Cardiovascular toxicity of some cancer agents (others than anthracyclines, fluoropyrimidines and trastuzumab);Toxicités cardiaques de quelques agents anticancéreux (autres que anthracyclines, fluoropyrimidines et trastuzumab)

Bulletin du Cancer

Volumn 91, Issue SPEC. ISS., 2004, Pages

  Saintigny, Pierre ^a   Chouahnia, Kader ^a   Charniot, Jean Christophe ^a   Breau, Jean Luc ^a  

^a AVICENNE HOSPITAL   (France)

Author keywords

Cardiovascular toxicity; Cytotoxic agents; Hormonotherapy; Immunotherapy

Indexed keywords

AMSACRINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ASPARAGINASE; BUSULFAN; CARMUSTINE; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DIETHYLSTILBESTROL; ETOPOSIDE; FLUOROPYRIMIDINE; GESTAGEN; IFOSFAMIDE; INTERFERON; INTERLEUKIN 2; IRINOTECAN; MITOMYCIN; PACLITAXEL; PENTOSTATIN; TAMOXIFEN; TENIPOSIDE; TRASTUZUMAB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER PATIENT; CARDIOTOXICITY; DRUG TOLERABILITY; HIGH RISK PATIENT; HORMONAL THERAPY; HUMAN; IMMUNOTHERAPY; IONIZING RADIATION; PROSTATE CANCER; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; HEART; HEART DISEASES; HUMANS; IMMUNOTHERAPY;

EID: 10044279508     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Muggia FM, Green MD, Speyer JL. Cancer treatment and the Heart. Baltimore and London: The Johns Hopkins University Press, 1992: 383.
2. Pai VB, Nahata MC. Cardiotoxiciry of chemotherapeutic agents. Incidence, treatment and prevention. Drug Saf 2000; 22: 263-302.
3. Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-42.
4. Shimoyama M, Murata Y, Sumi KI, et al. Docetaxel induced cardiotoxicity. Heart 2001; 86: 219.
5. Palma M, Mancuso A, Grifalchi F, et al. Atrial fibrillation during adjuvant chemotherapy with docetaxel: a case report. Tumori 2002; 88: 527-9.
6. Bissett D, Setanoians A, Cassidy J, et al. Phase I and pharmacokinetic study of taxotere (RP 56976) administred as a 24-hour infusion. Cancer Res 1993; 53: 523-7.
7. Valero V, Perez E, Dieras V. Doxorubicin and taxane combination regiments for metastatic breast cancer: focus on cardiac effects. Semin Oncol 2001; 28: 15-23.
8. Nabholtz JM, Flakson G, Campos D, et al. A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 127.
9. Cresta S, Grasselli G, Martoni G, et al. A randomized phase II study of alternating versus sequential versus combination of doxorubicin and docetaxel as 1st line chemotherapy in metastatic breast cancer patients. Proc Am Soc Clin Oncol 2001; 20: 190.
10. Holmes FA, Rowinsky EK. Pharmacokinetic profiles of doxorubicin in combination with taxanes. Semin Oncol 2001; 28: 8-14.
11. Minotti G, Saponiero A, Licata S, et al. Paclitaxel and docétaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001; 7: 1511-5.
12. Arbuck S, Strauss H, Rowinsky E, et al. A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer last 1993; 15: 117-30.
13. Ferrera JM, Magné N, Foa C, Largillier R, Namer M. Tolérance cardiaque des associations paclitaxel-anthracylines dans le cadre de la prise en charge du cancer du sein. Bull Cancer 2003; 90: 219-26.
14. Gianni L, Munzone E, Capri G, et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-99.
15. Gehl J, Boesgaard M, Paaske T, et al. Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 1996; 7: 687-93.
16. Gianni L, Dombernowsky P, Sledge G, et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 2001; 12: 1067-73.
17. Binganzoli L, Cufer T, Bruning P, et al. Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial. Cancer 2003; 97: 40-5.
18. Jassem J, Pienkowski T, Pluzanska A, et al., for the Central & Eastern Europe and Israel Paclitaxel Breast Cancer Study Group. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of arandomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-15.
19. Mamounas EP, Sledge GW. Combined anthracycline-taxane regimens in the adjuvant setting. Semin Oncol 2001; 28: 24-31.
20. Gennari A, Salvadori B, Donati S, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999; 17: 3596-602.
21. Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated with high dose cyclophosphamide therapy. Arch Intern Med 1981; 67: 235-44.
22. Cazin B, Gorin NC, Laporte JP, et al. Cardiac complications after bone marrow transplantation. A report on a series of 63 consecutive transplantations. Cancer 1986; 57: 2061-9.
23. Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide Cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-8.
24. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac changes with cyclophosphamide. Med Pediatr Oncol 1981; 9: 417-22.
25. Auner HW, Tinchon C, Brezinschek RI, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol 2002; 69: 1-6.
26. Mori T, Yanagi N, Maruyama T, et al. Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation. Jpn Heart J 2002; 43: 249-61.
27. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
28. Zenaide MNQ, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med 1993; 118: 31-6.
29. Skinner R, Pearson AD, Price L, et al. Nephrotoxicity after ifosfamide. Arch Dis Child 1990; 65: 732-8.
30. Verweij J, Funke-Kupper AJ, Teule GJ, et al. A prospective study on the dose dependency of cardiotoxicity induced by mitomycin C. Med Oncol Tumor Phamacother 1988; 5: 159-63.
31. Verweij J, Van der Burg MEL, Pinedo HM. Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug. Radiother Oncol 1987; 8: 33-41.
32. Rougier P, Bugat R. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin Oncol 1996; 23: 34-41.
33. Miya T, Fujikawa R, Fukushima JI, et al. Bradycardia induced by irinotecan: a case report. Jpn J Clin Oncol 1998; 28: 709-11.
34. Rothenberg ML, Meropol NJ, Poplin EA, et al. Mortality associated with irinotecan plus bolus fluorouracile/leucovorin: summary findings of an indenpendent panel. J Clin Oncol 2001; 19: 3801-7.
35. Benson III AB, Goldberg RM. Optimal use of the combination of irinotecan and 5-fluorouracile. Semin Oncol 2003; 30: 68-77.
36. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracile compared with fluorouracile alone as first-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet 2000; 355: 1041-7.
37. Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer 1975; 36: 1979-82.
38. Karminsky N, Merinsky O, Kovner F, Invar M. Vinorelbine-related acute cardiopulmonary toxicity. Cancer Chemother Pharmacol 1999; 43: 180-2.
39. Yancey RS, Talpaz M. Vindesine-associated angina and ECG changes. Cancer Treat Rep 1982; 66: 587-9.
40. Harris AL, Wong C. Myocardial ischaemia, radiotherapy, and vinblastine. Lancet 1981; 1: 787.
41. Aymard JP, Ferry R, Netter P, Balaud A, Streiff F. Toxicité cardiaque des alcaloïdes de la pervenche. Etude clinique de la littérature. Therapie 1985; 40: 361-4.
42. Talley RWO, Bryan RM, Gutterman JU, et al. Clinical evaluation of toxic effects ofcis-diasmine dichloroplatinum (NSC-119875) : Phase I clinical study. Cancer Chemother Rep 1973; 57: 465-71.
43. Rosenfeld CS, Broder LE. Cisplatin-induced autonomie neuropathy. Cancer Treat Rep 1984; 68: 659-60.
44. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science 1980; 208: 198-200.
45. Rozencweig M, Von Hoff DD, Henney JE, et al. VM-26 and VP-16-213: a comparative analysis. Cancer 1977; 40: 334-42.
46. Airey CL, Dodwell DJ, Joffe JK, et al. Etoposide-related myocardial infarction. J Clin Oncol 1995; 7: 135.
47. Kanj SS, Sharara AL, Shpall EJ, et al. Myocardial ischemia associated with high-dose carmustine infusion. Cancer 1991; 68: 1910-2.
48. Henner WD, Peters WP, Eder JP, et al. Pharmacokinetics and immediate effects of high-dose carmustine in man. Cancer Treat Rep 1986; 70: 887-91.
49. Terpstra W, De Maat CEM. Pericardial fibrosis following busulfan treatment. Neth J Med 1989; 35: 249-52.
50. Weinberger A, Pinkhas J, Sandbank U, et al. Endocardial fibrosis following busulfan treatment. JAMA 1975; 231: 495.
51. Donehower RC, Karp JE, Burke PJ. Pharmacology and toxicity of high-dose cytarabine by 72-hour continuous infusion. Cancer Treat Rep 1986; 70: 1059-63.
52. Castleberry RP, Crist WM, Holbrook T, et al. The cytosine arabinoside syndrome. Med Pediatr Oncol 1981; 9: 257.
53. Conard J, Cazenave B, Maury J, et al. L-asparaginase, antithrombin III, and thrombosis. Lancet 1980; 1: 1091.
54. Fragassi G, Pastore MR, Vicari A, et al. Myocardial infarction in a patient with acute lymphoblastic leukimia during L-asparaginase therapy. Am J Hematol 1995; 48: 136-7.
55. Kraut EH, Grever MR, Bouroncle BA. Long-term follow-up of patients with hairy cell leukaemia after treatment with 2-deoxycoformycin. Blood 1994; 84: 4061-3.
56. Grem JL, King SA, Chun HG, et al. Cardiac complications observed in elderly patients following 2-deoxycofotmycin therapy. Am J Hematol 1991; 38: 245-7.
57. Koczwara B, Spangenthal E, Bernstein SH. The development of congestive cardiac failure in a patient with hairy cell leukaemia treated with 2-chlorodeoxyadenosine. Leuk Lymphoma 1997; 26: 413-5.
58. Weiss RB, Grille-Lopez AJ, Marsoni S, et al. Amsacrine-associated cardiotoxicity: an analysis of 82 cases. J Clin Oncol 1986; 4: 918-28.
59. Steinherz LJ, Steinherz PG, Mangiacasale D, et al. Cardiac abnormalities after AMSA administration. Cancer Treat Rep 1982; 66: 483-8.
60. Kalapura T, Krishnamurthy M, Reddy CV. Acute myocardial infarction following gemcitabine therapy. A case report. Angiology 1999; 50: 1021-5.
61. Ciotti R, Belotti G, Facchi E, et al. Sudden cardio-pulmonaty toxicity following a single infusion of gemcitabine. Ann Oncol 1999; 10: 997.
62. Santini D, Tonini G, Abbate A, et al. Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity. Ann Oncol 2000; 11: 479-81.
63. Munoz A, Mane JM, Rubio I, et al. Gemcitabine and vascular toxicity. Lung Cancer 2002; 37: 229.
64. Grigg A, Szer J, Skov K, et al. Multi-organ dysfunction associated with high-dose carboplatin therapy prior to autologous transplantation. Bone Marrow Transplant 1996; 17: 67-74.
65. Gomez M, Villuendas R, Seres L, et al. Cardiac toxicity by carboplatin. Med Clin 2003; 121: 436.
66. McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003; 61: 3-7.
67. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58: 108-13.
68. Caine GJ, Stonelake PS, Rea D, et al. Coagulopathic complications in breast cancer. Cancer 2003; 98: 1578-86.
69. The ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC trial efficacy and safety update analyses. Cancer 2003; 98: 1802-10.
70. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifene therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-92.
71. Cutuli B, Petit JC, Fricket JP, et al. Accidents thromboemboliques chez les patientes ttaitées par tamoxifène en situation adjuvante. Fréquence, facteuts de risque et prévention. Bull Cancer 1995; 82: 51-6.
72. Ferrari E, Taillan B, Gibelin P, et al. Les complications cardiovasculaires de l'interféron. Ann Cardiol Angeiol (Paris) 1992; 41: 437-41.
73. Friess G, Brown T, Wrenn R, et al. Cardiac rhythm effects of gamma interfeton. Proc Am Soc Clin Oncol 1986; 5: 879.
74. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99: 557-61.
75. White RL, Schwartzentruber DJ, Guleria A, et al. Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 1994; 74: 3212-22.
76. Ravaud A, Negrier S, Lakdja F, et al. Effets secondaires de l'interleukine-2. Bull Cancer 1991; 78: 989-1005.
77. Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991; 9: 694-704.
78. Tourani JM, Pfister C, Tubiana N, et al. Subcutaneous interleukine-2 and Interferon alpha administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, non randomized study with sequential analysis design. The SubCutaneous Administration Propeukin Program cooperative group. J Clin Oncol 2003; 21: 3987-94.
79. Frankel SR, Eardley A, Heller G, et al. All-transretinoic acid for acute promyelocytic leukemia. Ann Intern Med 1994; 120: 278-86.
80. Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treatment with and without all-trans retinoic acid. Leak Lymphoma 1996; 20: 435-9.